AI could add $14T to global economy—but work still remains

As more businesses begin to implement state-of-the-art technologies, one industry expert is predicting AI will boost the global economy by $14 trillion by the year 2035.

According to a report from Fortune, Marc Carrell-Billiard, global senior managing director at Accenture Labs, shared that figure while speaking at the World Summit AI 2019 event in Amsterdam on Oct. 9. Carrell-Billiard also predicted, according to the same report, that AI will not be replacing the high number of jobs some other experts have suggested.

In addition, Carrell-Billiard observed that researchers have their own challenges to overcome as they continue to develop AI technologies. It can’t grasp context, for instance, in a way that a human can—not yet, at least.

Gary Marcus, a professor from New York University who has published a book about AI, seems to agree that this is an area where significant work is still needed, noting that AI can’t be trusted yet in areas such as healthcare. “The number of radiologists who’ve been replaced by deep-learning systems? Zero,” he said, according to Fortune.

To read the full story, which includes more about Carrell-Billiard and World Summit AI 2019, click the link below.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.